To this end, a soon-to-open phase 1 trial based upon our preclinical data will study the safety and activity of TSLPRCART immunotherapy in children and AYAs with relapsed/refractory CRLF2+ leukemias, including Ph-like ALL and DS-ALL. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.